In Brief: Angeion
This article was originally published in The Gray Sheet
Angeion: Files premarket approval application with FDA for its Sentinel 2000, 2010, 2011 and 2012 series implantable cardioverter defibrillator systems. The electronic PMA submission comes "just 15 months" after initiating U.S. clinical studies of the devices, the firm says ("The Gray Sheet" April 7, In Brief)...
You may also be interested in...
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake – but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.